The PTSD-Repository is a comprehensive database of PTSD trials. The PTSD-Repository allows clinical, research, education, and policy stakeholders to understand current research on treatment effectiveness and harms, and enable informed decisions about future research, mental health policy, and clinical care priorities. This report updates the studies and variables included in the PTSD-Repository to include recently published trials, interventions targeting comorbid PTSD/SUD (substance use disorder), variables related to comorbidities such as suicide and SUDs, and risk of bias (ROB) assessment.

The Comparative Effectiveness Review (Update Report) and Evidence Tables (Appendix E, F-1, & G-1) are included in the downloadable .zip file. For more information, visit AHRQ's page, and open the "Previous Versions" tab: https://effectivehealthcare.ahrq.gov/products/ptsd-pharm-non-pharm-treatment/research

Article from the Journal of Traumatic Stress (2020) by Maya E. O’Neil, Juliette M. Harik, Marian S. McDonagh, Tamara P. Cheney, Frances C. Hsu, David C. Cameron, Kathleen F. Carlson, Sonya B. Norman, and Jessica L. Hamblen.

Abstract: Given the extensive research on posttraumatic stress disorder (PTSD) treatment, a single, updatable repository of data from PTSD treatment studies would be useful for clinical, research, and policy stakeholders. To meet this need, we established a preliminary dataset of abstracted PTSD trial data, which serve as the basis for the PTSD Trials Standardized Data Repository (PTSD-Repository), maintained by the National Center for PTSD (NCPTSD).We followed systematic review methods to identify published randomized controlled trials (RCTs) of PTSD interventions. We consulted with a panel of experts to determine a priori inclusion criteria, ensure that we captured all relevant studies, and identify variables for abstraction. We searched multiple databases for materials published from 1980 to 2018 and reviewed reference lists of relevant systematic reviews and clinical practice guidelines. In total, 318 RCTs of PTSD interventions that enrolled almost 25,000 participants were included. We abstracted 337 variables across all studies, including study, participant, and intervention characteristics as well as results. In the present paper, we describe our methods and define data elements included in the data tables. We explain coding challenges, identify inconsistencies in reporting across study types, and discuss ways stakeholders can use PTSD-Repository data to enhance research, education, and policy. The abstracted data are currently publicly available on the NCPTSD website and can be used for future systematic reviews and identifying research gaps and as an information resource for clinicians, patients, and family members.

Citation: O'Neil, M. E., Harik, J. M., McDonagh, M. S., Cheney, T. P., Hsu, F. C., Cameron, D. C., Carlson, K. F., Norman, S. B., & Hamblen, J. L. (2020). Development of the PTSD-Repository: A publicly available repository of randomized controlled trials for posttraumatic stress disorder. Journal of Traumatic Stress, 33, 410-419. https://doi.org/10.1002/jts22520

This document contains brief descriptions of many of the treatments found in the PTSD-Repository, organized by treatment category.

The purpose of this project was to identify and abstract data from randomized controlled trials (RCTs) of posttraumatic stress disorder (PTSD) interventions to support the development of a publicly accessible data repository by the National Center for Posttraumatic Stress Disorder.

The 2019 Report and Evidence Tables (Appendix E & F) are included in the downloadable .zip file. For more information, visit AHRQ's page, and look under "Previous Versions" tab: https://effectivehealthcare.ahrq.gov/products/ptsd-pharm-treatment/research

The U.S. Department of Veterans Affairs (VA) has established a long-term partnership to commission AHRQ to utilize its Evidence-based Practice Centers to develop update reviews to inform the VA’s PTSD-Repository – a publicly accessible clinical trials database maintained by the National Center for PTSD (NCPTSD).

The 2022 Report and Evidence Tables (Appendix F, G1, & G2-3) are included in the downloadable .zip file. For more information, visit AHRQ's page: https://effectivehealthcare.ahrq.gov/products/ptsd-pharm-treatment/research